Abstract
The aim of this study was to evaluate the recently developed PANArray™ Human papilloma virus (HPV) kit for detection and genotyping of 19 high-risk and 13 low-risk HPV types, and compare it with the commercially available DNA chip kit genotyping of 24 HPVs. We collected cervical swabs from 741 patients with various stages of invasive cervical carcinoma being treated at the Samsung Medical Center. The overall HPV positivity rate was 73% using PANArrayTM HPV and 72.1% with the DNA chip, and no statistically significant differences were found with respect to the cytology grade. Comparing the results of the two chips, concordant results were found in 637/741 samples (85.9%), compatible in 69/741 (9.3%) and discordant in 35/741 (4.7%). Type-specific sequencing analysis of all samples revealed a 99.7% confirmation of PANArrayTM HPV genotyping results, compared to 91.0% of DNA chip. The PANArrayTM HPV test thus proved to be highly sensitive and accurate even when multiple HPV infections were present.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
